We are seeing patients in-person and through Video Visits. Learn more about how we’re keeping you safe and please review our updated visitor policy. Please also consider supporting Weill Cornell Medicine’s efforts to support our front-line workers.
Sandra and Edward Meyer Cancer Center

Warning message

The subscription service is currently unavailable. Please try again later.

You are here

News

Alternatives to Aggressive Therapy in Mantle Cell Lymphoma

Thursday, February 4, 2016

Peter Martin, M.D., assistant professor of Medicine in the Division of Hematology/Oncology, talks to Targeted Oncology about the evolving paradigm of treatment for mantle cell lymphoma. Martin says the evolution of the paradigm currently includes Bruton's tyrosine kinase inhibitor, phosphoinositide 3-kinase inhibitor, immunomodulatory treatments, and immunotherapies.

Martin says all the drugs mentioned have shown varying degrees of activity in mantle cell lymphoma, especially in the frontline setting. For patients with mantle cell lymphoma who are not amenable to particularly aggressive therapies, these treatments may provide alternative options.